Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas

Lin, Zhenying; Wang, Luanhong; Huang, Guang; Wang, Wenyan; Lin, Han Chieh

doi:10.1007/s00383-018-4347-9

Cited by 17 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Zhou et al [ 76 ] observed that propranolol prevented T-regulator lymphocyte elevation. Another potential cellular signaling pathway is adrenergic activation of PI3K/AKT and HIF-1 α, which is also inhibited by propranolol [ 77 ].…”

Section: Beta-blockersmentioning

confidence: 99%

Breast Cancer and Anaesthesia: Genetic Influence

Ponferrada

Orriach

Ruiz

et al. 2021

IJMS

View full text Add to dashboard Cite

Breast cancer is the leading cause of mortality in women. It is a heterogeneous disease with a high degree of inter-subject variability even in patients with the same type of tumor, with individualized medicine having acquired significant relevance in this field. The clinical and morphological heterogeneity of the different types of breast tumors has led to a diversity of staging and classification systems. Thus, these tumors show wide variability in genetic expression and prognostic biomarkers. Surgical treatment is essential in the management of these patients. However, the perioperative period has been found to significantly influence survival and cancer recurrence. There is growing interest in the pro-tumoral effect of different anaesthetic and analgesic agents used intraoperatively and their relationship with metastatic progression. There is cumulative evidence of the influence of anaesthetic techniques on the physiopathological mechanisms of survival and growth of the residual neoplastic cells released during surgery. Prospective randomized clinical trials are needed to obtain quality evidence on the relationship between cancer and anaesthesia. This document summarizes the evidence currently available about the effects of the anaesthetic agents and techniques used in primary cancer surgery and long-term oncologic outcomes, and the biomolecular mechanisms involved in their interaction.

show abstract

Section: Beta-blockersmentioning

confidence: 99%

Breast Cancer and Anaesthesia: Genetic Influence

Ponferrada

Orriach

Ruiz

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…23,24,[32][33][34] It revealed successful results in other vascular diseases like hemangiomas. [35][36][37][38][39] Propranolol could prevent tumour growth and some of the complications, like exudation or macular edema that could lead these patients to different grades of visual impairment. 12 In our study, we observed that visual acuity remained stable in the patients who took oral propranolol (120-240 mg/day).…”

Section: Discussionmentioning

confidence: 99%

Oral Propranolol in Von Hippel Lindau Ocular Affection

González-Rodríguez¹,

González-Rodríguez²,

Ramírez³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose. von Hippel Lindau (VHL) disease is a familiar syndrome associated with benign and malignant tumors. These tumors appear in the retina, cerebellum, spinal cord, and kidney. Retinal hemangioblastomas are one of the earliest and most frequent manifestations of this entity, and they can lead to blindness at a young age. Propranolol could be a promising treatment for retinal hemangioblastomas in von Hippel Lindau disease. Methods. Prospective cohort study. Seven patients with VHL disease and ocular affection that had rejected conventional treatment were included. Prospective analysis of seven patients was performed. We evaluated them for three years, with a complete ophthalmic evaluation that included: visual acuity, intraocular pressure, an examination of the anterior segment of the eye, fundoscopy, retinography, and optical coherence tomography (OCT). Heart rate and blood pressure on each patient were also measured. During the follow-up evaluation, two patients discontinued the treatment with propranolol after the first year and rejected any further treatment for their ocular affection; the rest continued therapy for the three years. Results: Visual acuity and tumor areas remained stable in 4 patients. Increased and new retinal exudation area was found in the two patients that discontinued the treatment with oral propranolol. Conclusions: Oral propranolol has shown a role in the reabsorption of retinal exudates in patients with von Hippel Lindau affection. It could delay or stabilize the ocular disease, maintaining visual acuity, and avoiding further complications in these patients. It is a well-known and available drug, without so many secondary effects, that could also have a role in other ocular diseases that course with exudation.

show abstract

“…It has been proposed that multiple hormonal factors, including β-adrenergic catecholamines, epinephrine, norepinephrine, and vascular endothelial growth factors (VEGF) are involved in the pathogenesis and progression of hemangiomas ( Boscolo and Bischoff, 2009 ). β-blockers may confer therapeutic efficacy for IH via inhibiting various related signaling pathways and cellular components, including thrombospondin-1, nuclear factor-κB, phosphatidylinositol 3-kinase, protein kinase B, mitogen-activated protein kinase, and hypoxia-inducible factor-1 ( Munabi et al., 2016 ; Lin et al., 2018 ; Xu et al., 2018 ). Studies are needed to determine the key mechanisms underlying the therapeutic role of β-blockers for IHs and to explore whether timolol and propranolol have synergetic pharmacological mechanisms that protect against the pathogenesis and progression of hemangiomas.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials

et al. 2020

View full text Add to dashboard Cite

Background Oral propranolol has become the first-line treatment for infantile hemangioma (IH). However, combined therapy with topical timolol and oral propranolol has been proposed as a more effective IH treatment strategy. We aimed to compare the safety and efficacy of topical timolol, oral propranolol, and their combination for treating IH in a meta-analysis. Methods Relevant randomized controlled trials (RCTs) were obtained after searching the PubMed, Embase, Cochrane’s Library, China National Knowledge Infrastructure, and WanFang databases. A random-effect model was used to pool the results. Results Eight RCTs with 759 patients with IH were included in this meta-analysis. Treatment with topical timolol alone showed a similar response rate compared to oral propranolol (risk ratio [RR] = 0.97, p = 0.63), but resulted in fewer adverse events (RR = 0.36, p = 0.002). Combined treatment with topical timolol and oral propranolol showed a favorable response rate compared to treatment with oral propranolol (RR = 1.14, p = 0.03) or topical timolol (RR = 1.36, p = 0.01) alone. Moreover, combined treatment showed similar risks of adverse events compared to oral propranolol (RR = 0.80, p = 0.24) or topical timolol (RR = 1.31, p = 0.25) alone. Conclusions Combined treatment with topical timolol and oral propranolol may be more effective than either single treatment strategy in patients with IH. Topical timolol alone conferred similar efficacy for IH compared to oral propranolol, but with less incidence of adverse events.

show abstract

Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas

Abstract: Propranolol can promote regression of infantile hemangiomas, which may be related to the inhibition of PI3K, AKT, and HIF-1α activity.

Cited by 17 publications

References 12 publications

Breast Cancer and Anaesthesia: Genetic Influence

Breast Cancer and Anaesthesia: Genetic Influence

Oral Propranolol in Von Hippel Lindau Ocular Affection

Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About